(Q40635141)

22 September 2017

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium (English)

1 reference

22 September 2017

1 reference

1 reference

Sweeney CJ

1

1 reference

22 September 2017

Williams SD

2

1 reference

22 September 2017

Finch DE

3

1 reference

22 September 2017

Bihrle R

4

1 reference

22 September 2017

Foster RS

5

1 reference

22 September 2017

Collins M

6

1 reference

22 September 2017

Fox S

7

1 reference

22 September 2017

Roth BJ

8

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

22 September 2017

1 reference

22 September 2017

86

1 reference

22 September 2017

514-518

1 reference

22 September 2017

3

1 reference

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

22 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C514%3A%3AAID-CNCR21%3E3.0.CO%3B2-9

10.1002/(SICI)1097-0142(19990801)86:3<514::AID-CNCR21>3.0.CO;2-9

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference